Science. 2024 Sep 20. 385(6715): 1338-1347
Johannes Popow,
William Farnaby,
Andreas Gollner,
Christiane Kofink,
Gerhard Fischer,
Melanie Wurm,
David Zollman,
Andre Wijaya,
Nikolai Mischerikow,
Carina Hasenoehrl,
Polina Prokofeva,
Heribert Arnhof,
Silvia Arce-Solano,
Sammy Bell,
Georg Boeck,
Emelyne Diers,
Aileen B Frost,
Jake Goodwin-Tindall,
Jale Karolyi-Oezguer,
Shakil Khan,
Theresa Klawatsch,
Manfred Koegl,
Roland Kousek,
Barbara Kratochvil,
Katrin Kropatsch,
Arnel A Lauber,
Ross McLennan,
Sabine Olt,
Daniel Peter,
Oliver Petermann,
Vanessa Roessler,
Peggy Stolt-Bergner,
Patrick Strack,
Eva Strauss,
Nicole Trainor,
Vesna Vetma,
Claire Whitworth,
Siying Zhong,
Jens Quant,
Harald Weinstabl,
Bernhard Kuster,
Peter Ettmayer,
Alessio Ciulli.
Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.